pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,171 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT819Endpoints616BioPharma Dive237onclive165Fierce Biotech84BioSpace83raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
    None of STAT's requests for Kennedy's schedule have been completed, and some haven't even been acknowledged.
    STAT · 1mo ago↗ source
  • Drinking during pregnancy rose after 2020, new CDC data suggest
    A new CDC report underscores that drinking during pregnancy, while generally thought of as a thing of the past, is still a matter of concern.
    STAT · 1mo ago↗ source
  • STAT+: AMA and lawmakers push back on AI care denials
    In this edition of STAT Health Tech: HHS watchdog on denials by health insurers, lawmakers target AI denials, and Talkspace's new chatbot offering.
    STAT · 1mo ago↗ source
← prev
page 25 of 47
next →
21
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Nonprofit buys experimental cancer drug to maintain patient access
    In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer drug.
    STAT · 1mo ago↗ source
  • Study highlights influence of socioeconomic status on children’s brain development
    A new study found that the leading environmental factor influencing brain structure and function is the socioeconomic status of a child's family.
    STAT · 1mo ago↗ source
  • STAT+: Abridge inks deals with Nvidia and Lilly
    Abridge announced new deals with Eli Lilly and Nvidia as it aims to gain an edge in a competitive market.
    STAT · 1mo ago↗ source
  • Summit pulls $500M share sale a day after announcing it
    The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.
    BioPharma Dive · 1mo ago↗ source
  • Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
    A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: A suspicious denial pattern in Medicare Advantage
    Major Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.
    STAT · 1mo ago↗ source
  • Novartis RNA drug acquired in $12B Avidity deal notches a trial win
    The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Novartis doubles down on molecular glue strategy
    Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
    More employers are planning to drop coverage of GLP-1 drugs for weight loss next year as increasing numbers of people take the medications
    STAT · 1mo ago↗ source
  • STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
    A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, new data show.
    STAT · 1mo ago↗ source
  • STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A
    Proving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.
    STAT · 1mo ago↗ source
  • HHS responds coolly to paper on alcohol risk
    Soda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
    The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
    BioPharma Dive · 1mo ago↗ source
  • Opinion: We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850
    In 2025, Elizabeth Selvin and her colleagues published in Nature Medicine for free. In 2026, it cost them $12,850, she writes.
    STAT · 1mo ago↗ source
  • Opinion: How long Covid’s scientific stalemate made it politically erasable
    Long Covid hasn’t disappeared. It’s just gone underground, writes Steven Phillips.
    STAT · 1mo ago↗ source
  • STAT+: Scientists see promise in NIH proposal to cap number of grants they receive
    Without easy access to leaders within a field or top-of-the-line lab equipment, principal investigators outside top universities often struggle to compete for grants from the NIH.
    STAT · 1mo ago↗ source
  • STAT+: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find
    Federal investigation finds Medicare Advantage insurers block rehab care for older adults, only to reverse denials on appeal.
    STAT · 1mo ago↗ source
  • Diabetes association leader apologizes for expulsion of members, pledges to rebuild trust
    The American Diabetes Association CEO apologizes to five members kicked out of annual convention for distributing protest literature, launches review of what went awry.
    STAT · 1mo ago↗ source
  • STAT+: Your sepsis algorithm shouldn’t require a time machine
    In this edition of AI Prognosis: Quirky medical data tripping up sepsis algorithms, AI scribes for patients, and some AI biotech news.
    STAT · 1mo ago↗ source
  • Ethyreal starts up with $101M and takes aim at a pair of immune diseases
    The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
    BioPharma Dive · 1mo ago↗ source
  • Sanofi stops immune drug trial in latest research setback
    The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.
    BioPharma Dive · 1mo ago↗ source